Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.74 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.74 |
| ▸ | TNF | P01375 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 5/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
| ▸ | CSF1R | P07333 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230002 | 0.86 | CYP11B1 (1.00) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL31357411 | 0.86 | CYP11B1 (1.00) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL10930031 | 0.85 | CYP11B1 (0.73) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL13907295 | 0.84 | CYP11B1 (0.89) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL7138429 | 0.84 | LTA4H (0.80) | HTTSMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL27699770 | 0.83 | CYP11B1 (0.87) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL30789254 | 0.83 | CYP11B1 (0.60) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL30138392 | 0.82 | HTT (0.72) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL12771538 | 0.82 | HTT (0.72) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL9049676 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035092-A1 | Inhibit binding of alpha-v integrins to their ligands, use in treatment of immune and inflammatory disorders; 3-(4-(2-Aminoethyl)benzamide)-3-(2-(4-(2-pyridylamino)methyl) phenoxy)-4-pyrimidinyl)propanoic acid | CELLTECH THERAPEUTICS LIMITED | 2002-03-21 | — | — | US | disclosed |
| US-6319922-B1 | ALPHA-PYRIMIDYL-SUBSTITUTED; USEFUL FOR TREATING DISEASES INCLUDING INFLAMMATORY DISEASES, AND DISEASES INVOLVING ANGIOGENESIS, BONE RESORPTION OR CELLULAR OR MATRIX OVER-EXPANSION. | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035092-A1 | Inhibit binding of alpha-v integrins to their ligands, use in treatment of immune and inflammatory disorders; 3-(4-(2-Aminoethyl)benzamide)-3-(2-(4-(2-pyridylamino)methyl) phenoxy)-4-pyrimidinyl)propanoic acid | ITGA1, ITGB1, VCAM1 | CYP11B1 1957/4885CYP11B2 2766/4885TNF 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.